


OSE INTRODUCTION

MARCH 2023

O X F O R D
S C I E N C E
E N T E R P R I S E S



“Our vision is a world where the best scientists and brightest business minds combine to solve our biggest challenges at unprecedented speed.

”

Our unique partnership

Our partnership with the leading research University in the world is a huge differentiator and investment opportunity

Unique partnership model

Unique partnership OU has a non-dilutable 5% stake in OSE, and we receive an automatic 10% zero-cost stake in science spinouts

Early access Deep academic relationships lead to engagement with opportunities 1-2 years ahead of the market

Significant stakes early Build significant stakes early, before huge investment flows drive valuations up

Diverse pipeline of world changing science: from quantum to fusion to therapeutics to agtech

Rapidly expanding ecosystem

We continue to see **increasing external interest** and investment in Oxford:

- £100m antimicrobial research - Ineos
- £50m funding for vaccine research – Serum Life Sciences
- £4bn property development partnership with L&G

£1.4bn invested in Oxford companies in 2021 (2019: £380m)

2021 Oxford IPOs include:



IMMUNOCORE



Oxford University

World leading science

#1 university in the world and **#1 for research**, 7 years running¹

Inventors of world-changing technologies, from the lithium-ion battery, to the blood glucose test sensor, to the Oxford/AstraZeneca vaccine

26 science faculties, across Medical Sciences and the Mathematical, Physical and Life Sciences (MPLS)

- *Ranked #1 in the world for Clinical, Pre-Clinical and Health*²
- *Ranked #1 in the world for Computer Science*²

>1,800 academics, **c. 4,500** research and support staff, **>6,400** postgrads³, 56 **Nobel prize** winners⁴

>£809m annual external research funding³

Leading source of UK university spinouts² – creating **>200 businesses** since 1959⁵, a significant percentage created in the last 5 years.

World leading research across:

- *Medical science*
- *Quantum*
- *Computer science/cyber security*
- *Imaging*
- *Machine learning/AI/Robotics*
- *Engineering Science*
- *Astrophysics*

.....

1. [Times Higher Education World University Rankings 2022](#) 2. [University of Oxford website – Facts & Figures](#)

3. [Total research income including the grant from Research England – Oxford University 2020/1 accounts](#) 4. [University of Oxford Website – Award Winners](#)

5. [Oxford University creates its 200th spinout company](#)

OUR INVESTMENT STRATEGY

WE ARE THE FIRST CHEQUE IN AND BACK OUR COMPANIES ALL THE WAY TO EXIT

1. SCOUTING/EXPLORATORY

2. COMPANY BUILD

3. GROWTH/LATER STAGE

OPPORTUNITIES P.A.

20+

10-15

7-10

OSE INVESTMENT £

£250k-£500k

£2m-£10m

£10m-£20m

OSE STAKE

-

30-50%

20-30%

ACTIVITIES

EXPLORATORY BUILDS

- We invest from pre-seed, writing small, exploratory cheques
- Typically investing in 20+ opportunities per year
- Leveraging Scientists and Entrepreneurs-in-Residence

TRUE BUILDS

- We aim to spin-out 10-15 new companies per year
- Disciplined, milestone-driven process
- Build right leadership team to ensure success

NAV DRIVERS

- We follow our winners into later-stage rounds, writing larger cheques
- Attract value-add investors and supercharge Board and talent

World class business creation platform and best-in-class business scaling



Investment team - Specialists across Life Sciences, Deep Tech, Health Tech and Software/AI

EiRs & SiRs
Sector specialists to seed the science

Operating Partners
Leaders who have built and operated businesses

Late-stage, Public markets, and corporate finance experts

ENTERPRISE LABS
A platform providing access to playbooks, resources, suppliers, events, and advisors

Talent & Network
Building management teams and boards

Co-investors & Legal Identifying value add capital + deal negotiation

Advisors and Board NEDs

GRASS -ROOTS 12,000 sq. ft. **THE OXFORD SCIENCE PARK** 46,000 sq. ft.

Property: 58,000 sq. ft. of dedicated wet lab and incubator space, which we rent fully fitted, on flexible terms

Experienced Management Team – balance of investors, operators and company builders



Jim Wilkinson
CFO

- 30+ years commercial sector experience
- Ex CFO at Informa Group, Sportingbet, Johnson Service Group, and IBC Group



Katya Smirnyagina
Sr Partner – Life Sciences

- 20+ years investment experience
- Ex Alta, Capricorn Partners, and past Vice-Chair of InvestEurope



Martin Fiennes
Partner – Deep Tech

- 25+ years experience investing
- Ex Gatehouse Capital and Top Technology Ventures



Heather Roxborough
Partner – Health Tech

- 20+ years investment and company building experience
- Ex Optum Ventures, Unilever, and J&J



Sarah Shackelton
Chief Talent Officer

- 20+ years experience building boards and senior leadership teams
- 17 years working as Partner at Abingworth

We've raised **£863m of patient capital** from global investors who believe in our science and our vision.

wellcome^{trust}



Tencent 腾讯



OU endowment management

TEMASEK HOLDINGS

Redmile Group

Willis Towers Watson

LANSDOWNE PARTNERS




FOSUNPHARMA 复星医药

FRESTON VENTURES



OXFORD SCIENCE ENTERPRISES

DELIVERING IMPACT ACROSS FOUR KEY GOALS



ENABLING PEOPLE TO
LEAD LONGER,
HEALTHIER LIVES

+£400m invested by OSE
+£1bn invested by external investors
41 companies, now worth over **+£3.2bn**

Preventing, predicting, and diagnosing:



Oxford COVID-19 vaccine



AI diagnostic for heart disease



AI prediction for heart disease



Portable lab-quality diagnostics

Treating:



Rare diseases



Neuromuscular and genetic diseases



Orphan disease and immunological conditions



Autoimmune disease



Solid tumours, autoimmune, and infectious diseases

O X F O R D
S C I E N C E
E N T E R P R I S E S



PROTECTING THE
FUTURE OF OUR
PLANET

+£105m invested by OSE
+£120m invested by external investors
13 enterprises, now worth over **+£755m**

Clean energy:



Fusion energy



Concentrated solar power

Resource efficiency:



Battery management



Electric motors



Smart hot water tanks

Biodiversity:



Natural capital measurement



FEEDING THE WORLD
AND KEEPING US SAFE

+£50m invested by OSE
+£100m invested by external investors
11 enterprises, now worth over **+£460m**

Sustainable agriculture:



Sustainable herbicides



Crop upgrade platform



Precision crop intelligence

Safety:



Post-quantum cryptography



3D-printed helmets



Data Privacy

Education:



Digital textbooks




ACCELERATING THE
PACE OF POSITIVE
CHANGE

+£185m invested by OSE
+£325m invested by external investors
24 enterprises, now worth over **+£1.1bn**

Next-gen computing:



Quantum - superconducting



Quantum - ion trap



Quantum - photonic



Quantum - silicon



Hybrid photonic processor

Research tools:



Mass photometry



Nanoimager microscope

Industrial capability




Digital solutions for metal



Hyperspectral imaging

OXFORD ECOSYSTEM

WE ARE HELPING BUILD A PHENOMENAL SCIENCE-BUSINESS ECOSYSTEM IN OXFORD



Oxford University spinouts increased from an average of 4-5 companies per year in 2015 to over 20 per year in 2021

Investment in Oxford spinouts increased from an average of £125m per year (2011-2015) to >£600m per year (2016–2021)

Attracting an incredible influx of scientific and management talent from around the world



OUR ENTERPRISES ARE ATTRACTING SPECIALIST CAPITAL

OVER 200 CO-INVESTORS : NEW 2022 CO-INVESTORS INC. MEDICXI, PFIZER VENTURES, UNIVERSITY OF TOKYO EDGE CAPITAL & PROSUS VENTURES



FINANCIALS

DOUBLE DIGIT GROWTH IN NAV PER SHARE DURING 2022

OVER SEVEN YEARS WE HAVE:

- Raised **£863m** from investors who believe in our science and vision
- Driven attractive financial returns
 - Portfolio IRR of **28%** Sept 2015 to Dec 2022
 - Blended MM of **1.86x**
- Invested **£608m in portfolio** of enterprises currently valued at **£785m** + total realisations of **£311m**
- Established **20%+ stakes** in significant number of businesses starting to hit material inflection points
- Adding **10-15** potential transformative opportunities each year

OVER THE LAST 12 MONTHS:

- Over **£600m** invested in portfolio, **£161m** by OSE
- Portfolio valuation at **£785m (+27%)**
- Operating expenses of £15.4m **down 6%** (2021: £16.3m) driven by operational improvements
- Overall, 2022 NAV up 10% to **£1.27m**
 - NAV/ share of **162p**
- Dec-22 cash on balance sheet **£467m**

Summary

- Integration with OU gives us **early access to a proprietary pipeline** that allows us to **build big stakes early**
- We have an **experienced and balanced team**
- **Material value inflection points** from businesses founded 3-6 years ago are starting to come through
- **10-15 potential transformative opportunities** being added each year
- We are focused on **generating attractive returns** and impact over the long-term